Literature DB >> 32009163

PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.

Masaaki Sawada1,2, Kumiko Goto1,3, Akiko Morimoto-Okazawa1,2, Miya Haruna1,3, Kei Yamamoto1, Yoko Yamamoto1, Satoshi Nakagawa2, Kosuke Hiramatsu2, Shinya Matsuzaki2, Eiji Kobayashi2, Atsunari Kawashima4, Michinari Hirata1,3, Kota Iwahori1, Toshihiro Kimura2, Yutaka Ueda2, Tadashi Kimura2, Hisashi Wada1.   

Abstract

Persistent exposure to tumor antigens results in exhausted tumor-infiltrating T cells (TILs) that express the immune checkpoint molecules, PD-1 and Tim3, and lack anti-tumor immunity. To examine the exhausted status of TILs in ovarian cancer, the potential for cytokine production, proliferation and cytotoxicity by purified PD-1+ Tim3+ CD8 TILs was assessed. The production of IFN-γ and TNF-α by PD-1+ Tim3+ CD8 TILs remained the same in an intracellular cytokine staining assay and was higher in a cytokine catch assay than that by PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. %Ki67+ was higher in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- CD8 TILs. However, patients with high PD-1+ Tim3+ CD8 TILs had a poor prognosis. The potential for cytotoxicity was then examined. %Perforin+ and %granzyme B+ were lower in PD-1+ Tim3+ CD8 TILs than in PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. To observe the potential for direct cytotoxicity by T cells, a target cell line expressing membrane-bound anti-CD3scFv was newly established and a cytotoxic assay targeting these cells was performed. The cytotoxicity of PD-1+ Tim3+ CD8 TILs was significantly lower than that of PD-1- Tim3- and PD-1+ Tim3- CD8 TILs. Even though PD-1+ Tim3+ CD8 TILs in ovarian cancer showed a sustained potential for cytokine production and proliferation, cytotoxicity was markedly impaired, which may contribute to the poor prognosis of patients with ovarian cancer. Among the impaired functions of exhausted TILs, cytotoxicity may be an essential target for cancer immunotherapy. © The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cytokine production; cytotoxicity; exhaustion; membrane-bound anti-CD3scFv; proliferation

Year:  2020        PMID: 32009163     DOI: 10.1093/intimm/dxaa010

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Differential expression of Tim3 protein in colorectal cancer associated with MSI and Braf mutation.

Authors:  Shuyan He; Qingfeng Lin; Jie Chen; Chenglong Ma; Zhili Liu; Yuejun Sun; Weidong Mao; Dong Shen; Jiandong Wang
Journal:  Histol Histopathol       Date:  2022-01-07       Impact factor: 2.303

2.  [TIM-3 gene is highly expressed in ephithelial ovarian cancer to promote proliferation and migration of ovarian cancer cells].

Authors:  Y Huo; Y Wang; N An; X DU
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-02-20

3.  Circulating T Cells Exhibit Different TIM3/Galectin-9 Expression in Patients with Obesity and Obesity-Related Diabetes.

Authors:  Lili Sun; Shengyi Zou; Sisi Ding; Xuan Du; Yu Shen; Cuiping Liu; Bimin Shi; Xueguang Zhang
Journal:  J Diabetes Res       Date:  2020-10-15       Impact factor: 4.011

Review 4.  T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Authors:  Michael D Crowther; Inge Marie Svane; Özcan Met
Journal:  Cells       Date:  2020-06-30       Impact factor: 6.600

5.  Analysis of Prognostic Alternative Splicing Reveals the Landscape of Immune Microenvironment in Thyroid Cancer.

Authors:  Jian Wu; Yifang Sun; Junzheng Li; Maomao Ai; Lihua You; Jianbo Shi; Feng Yu
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

6.  The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.

Authors:  Miya Haruna; Azumi Ueyama; Yoko Yamamoto; Michinari Hirata; Kumiko Goto; Hiroshi Yoshida; Naoko Higuchi; Tetsuya Yoshida; Yujiro Kidani; Yamami Nakamura; Morio Nagira; Atsunari Kawashima; Kota Iwahori; Yasushi Shintani; Naganari Ohkura; Hisashi Wada
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

7.  Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.

Authors:  S M Castenmiller; R de Groot; A Guislain; K Monkhorst; K J Hartemink; A A F A Veenhof; E F Smit; J B A G Haanen; M C Wolkers
Journal:  Immunooncol Technol       Date:  2022-06-22

8.  The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.

Authors:  Jie Zhu; Peiqi Fang; Chong Wang; Meixiu Gu; Baishen Pan; Wei Guo; Xinrong Yang; Beili Wang
Journal:  Cancer Med       Date:  2021-10-04       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.